Pravin fianl


Published on

Published in: Business, Technology
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • In case of nonlinearity, a more sensitive species may be used
  • Pravin fianl

    1. 1. Dr. Pravinkumar Wahane JR II BJGMC, Pune Toxicity Studies
    2. 2. Source, Synthesis & chemistry Preclinical Studies & Toxicology Studies Animal models, Efficacy and Safety Clinical Trials Drug Development
    3. 3. Preclinical Safety & Toxicity Testing  Aims at discovering complications or sequelae arising from the pharmacological actions of drug and any unexpected side-effects.
    4. 4. Primary Goals Estimate safe starting dose for clinical studies & subsequent dose escalation schemes in humans. Identify potential target organs for toxicity and study whether such toxicity is reversible. Assess dose dependence & relationship to exposure Assess hazards that cannot be evaluated in clinical trials (e.g. carcinogenicity and teratogenicity) Identify hazards and estimate safe dose range
    5. 5. Necessity of toxicity studies  Completely novel compound of unique action under consideration  Any chemical modification made to a known drug  Formulations of a compound are considered ( Separately as well as formulated form)  Novel combination of drugs made available as a single formulation  Veterinary drugs → if treatment is given to animals intended for human food
    6. 6. Requirements  Chemical Criteria  Substance used in toxicity studies should be as pure as material to be given to man
    7. 7. Materials: Animals  Species:  Species difference → single largest difficulty in interpretation of toxicity studies  Species →health, behaviour, endemic disease and reaction to well studied toxic agent is familiar  Two different species(Rodent & Non Rodent) used  Should differ phylogenetically as widely as possible
    8. 8. Materials: Animals  Species:  Species in which test material is pharmacologically active due to presence of receptor should be used Ex. Avoid dogs for studying toxic effects of sulphonamides, monkeys are better  Strains:  Use either animals derived from random breeding in a closed colony or hybrids of two inbred lines
    9. 9. Materials: Animals  Number, age and sex:  Should be sufficient  Long term experiments i.e. Carcinogen testing, large number may be necessary to detect relatively low incidence of the reactions  Young immature animals are preferred generally → rapid growth, but for detection of actions on endocrine and reproductive systems, sexually mature animals are required  Should include groups of both males and females
    10. 10. Route / Frequency of administration  Two routes to be used, one should be which is intended for clinical use  Aim should be to maintain the appropriate blood and tissue level of the compound under consideration for test duration
    11. 11. Duration  Depends on type of the test (acute, sub-acute, chronic)  All the important toxic effects of test substances can probably predicted from experiments lasting no more than three months  In the absence of any rational basis for choosing a period, a duration of twice the maximum exposure likely for the human beings is convenient guide. 2 yrs. max
    12. 12. Toxicity Studies  Systemic Toxicity studies  Reproductive toxicology studies  Local Toxicity studies  Allergenicity/ Hypersensetivity studies  Genotoxicity studies  Carcinogenicity studies
    13. 13. Systemic Toxicity Studies
    14. 14. Single dose (Acute) Short term repeated dose (Subacute) Repeated dose: 10% life-span (Subchronic) Repeated dose: >10% life span (Chronic) Systemic Toxicity Studies
    15. 15. Single-dose (Acute) Toxicity Studies  Dose – toxicity relationship  Specific toxic effects  Mode of toxic action  Median Lethal dose (LD 50)  Route dependent toxicity  Sex dependent toxicity
    16. 16. Single-dose (Acute) Toxicity Studies  Rodent species (mice and rats)  Use the same route as intended for humans  Use at least one more route in one of the species. This  Ensures systemic absorption of the drug (unless the intended route in humans is only intravenous)  Recommended limit for oral dosing : Higher value of either  2000 mg/kg or  10 times the normal dose that is intended in humans
    17. 17. Single-dose (Acute) Toxicity Studies  At least 5 animals / sex / group  At least 4 graded doses (4 dose-groups)  Observation for toxic effects (if any) : 14 days  Obsevation for mortality :  7 days [parenteral administration]  14 days [oral administration]
    18. 18. Up and down procedure (Guideline 425) (End point: mortality) Preliminary study : 1 animal per step Starting dose : just below expected LD 50 Dose stepped up / down by a factor of 3.2 Continued till outcome reversed, i.e. mortality <=> survival  Reduction of the number of animals, use of single sex  Preliminary studies, followed by main test (Limit test) Fixed dose procedure (Guideline 420) (End point: Evident toxicity) Sighting study : 1 animal per step Starting dose : expecting some toxicity Fixed doses of 5, 50, 300 and 2000 mg/kg Dose stepped up / down till end-point achieved Acute toxic class (Guideline 423) (End point: mortality) 3 animals of one sex / step Initial dose: expecting mortality in some animals Fixed doses of 5, 50, 300 and 2000 mg/kg Dose stepped up / down till end point achieved Modifications (OECD guidelines: 420, 423, 425; yr 2000)
    19. 19. Other parameters :  Symptoms, signs and mode of death  LD 10 and LD 50 values, preferably with 95 % CI Genetic effects if any Establish the:  Minimum lethal dose (MLD)  Maximum tolerated dose (MTD)  Target organ of toxicity (if possible)
    20. 20. Cytotoxic anticancer agents  MTD determined first in Mice  Findings in Rat confirmed to establish a linear relationship between toxicity and body surface area  MTD can be established in non-rodent species, if:  Predictability is known to be poor in Rodents (e.g. Antifolates)  Drug has a novel mechanism of action
    21. 21. Toxicokinetic studies Generation of pharmacokinetic data (ADME): • A part of non-clinical toxicity studies or • A separate supportive study Purpose: • Assessment of systemic exposure of test substance • Relationship of toxicology to dose and time course • Choose species & regimen in subsequent toxicity studies • Designing of subsequent non-clinical toxicity studies
    22. 22. Rodents • One rodent species (preferably rat) • At least 4 graded doses including control • Minimum of 5 animals of each sex • Proposed clinical route of administration • Test substance given daily for 10 consecutive days Non-Rodents • One male and one female (Dogs > Primates) • Starting dose (3 or 5 x extrapolated effective dose) or MTD (whichever is less) • Dose escalation every 3rd day, lowered if toxicity seen • Then test substance given daily for 10 consecutive days Dose-ranging study  Establishment of MTD for repeated dose studies  Identification of Target organ of toxicity
    23. 23. Repeated-dose Toxicity Studies  Duration depends on proposed clinical trial  At least 2 species, one non-rodent  Species-specific pharmacokinetics, if any, should preferably resemble human beings  Route intended for human clinical use
    24. 24. Repeated-dose Toxicity Studies  Wherever applicable, include a Control group  3 other groups are formed, as:  Highest dose Observable toxicity [MTD]  Lowest dose No observable toxicity [NOAEL] intended therapeutic dose or multiple of it  Intermediate dose Some symptoms ; not gross toxicity or death placed logarithmically betn doses
    25. 25. • Rodent : 6-10/sex/group • Non-rodent : 2-3/sex/group 14-28 Day repeated-dose (Subacute toxicity studies) • Rodent : 15-30/sex/group • Non-rodent : 4-6/sex/group 90-Day repeated-dose (Subchronic toxicity studies) • Rodent : 15-30/sex/group • Non-rodent : 4-6/sex/group 180-Day repeated-dose (9 months for non rodents?) (Chronic toxicity studies)
    26. 26. In all cases:  Behavioural : General appearance, activity, behaviour  Physiological : Body weight, food intake  Biochemical : Hematology, serum and urine analysis  Pathological : Organ weights, gross & microscopic study of viscera & tissues Parameters to be monitored •If parenteral drug administration:  Injection site : Gross and Microscopic examination •In non-rodent species:  Electrocardiogram : Initial and Final  Fundus examination
    27. 27. Reproductive Toxicology
    28. 28. Reproductive Toxicity  Male Fertility  Female Reproduction & Developmental toxicity  Female Fertility  Teratogenicity  Perinatal development
    29. 29. Male Fertility Study  One rodent species (preferably rat)  3 dose groups and a control group :  Dose selection : results of previous 14 or 28-day toxicity study  Highest dose : showing minimal toxicity in systemic studies  6 adult male animals per group
    30. 30. Test substance by intended route of use for : • minimum 28 days • maximum 70 days Paired with female animals of proven fertility in a ratio of 1:2 Drug treatment of male animals continues during pairing Pairing continued till detection of Sperm in vagina or 10 days, whichever is earlier
    31. 31. Pregnant females examined after day 13 of gestation Males sacrificed at the end of the study Weights of each testis and epididymis recorded Sperms from one epididymis examined for motility and morphology Other epididymis and both testes examined for histology
    32. 32. Female Reproduction and Developmental Toxicity Studies  For all drugs proposed for women of child bearing age • Segment I : Female fertility • Segment II : Teratogenicity • Segment III : Perinatal development  Segment I, II and III studies in albino mice or rats, and  Segment II study also in albino rabbits as a second test species
    33. 33. Female Fertility Study (Segment I)  One rodent species (rat preferred)  3 graded doses  Highest dose : doesn’t affect general health of parent animals (usually the MTD from previous systemic studies)  At least 15 males and 15 females per dose group  Route of administration same as intended for therapeutic use
    34. 34. Pups : Physiology, Behaviour, Pathology (sex-wise distribution noted) Body weight Food intake Clinical signs of intoxication Reproduction and Parturition Pathology Gross & Micro Females allowed to litter, medication continued till weaning of pups Drug treatment continued during mating and gestation period Drug administration : 28 days (males) & 14 days (females) before mating
    35. 35. Teratogenicity Study (Segment II)  Rodent (preferably rat) and Non-rodent (rabbit)  Drug administered throughout organogenesis  3 dose levels and a Control group:  Highest dose : minimum maternal toxicity  Lowest dose : as proposed clinical dose or its multiple  Route of administration : same as intended for humans  At least 20 pregnant rats (or mice) and 12 rabbits, for each dose
    36. 36. Observation parameters Females General Signs of intoxication Body weight Food intake Reproductive Uterus, Ovaries Products of conception Foetuses General Number Gender Length Weight Pathology Gross (all) Visceral (half) Skeletal (half)
    37. 37. Perinatal Study (Segment III)  Specially if → Drug to pregnant / nursing mothers for long periods → Indications of possible adverse effects on foetus  One rodent species (preferably rat)  Dosing comparable to multiples of human dose and route  At least 4 groups (including control), 15 females / group  Drug throughout last trimester (from day 15 of gestation)  Dose causing low foetal loss continued throughout weaning
    38. 38. F1 litter 1 male and 1 female from each group Test substance given Throughout growth to sexual life Mating performance and fertility of F1 : F2 generation F2 generation growth parameters monitored till weaning
    39. 39. Local Toxicity
    40. 40. Local Toxicity  Dermal Toxicity  Ocular Toxicity  Vaginal Toxicity  Rectal tolerance test  Parenteral Drugs Tolerance  Inhalation toxicity
    41. 41. Local Toxicity  If intended for special route (other than oral) in humans  Appropriate site (e.g., skin or vaginal mucous membrane) in a suitable species  Preferably use of 2 species  3 dose levels and untreated and / or vehicle Control  If the drug is absorbed systemically, appropriate systemic toxicity studies also required
    42. 42. Dermal Toxicity  As cutaneous contamination is always a possibility  Rabbit and Rat  Applied on shaved skin  Concentrations 7 fold higher than the clinical doses  Period of application : 7 to 90 days  Evaluation › Local signs (erythema, oedema and eschar formation) › Histological examination of sites of application
    43. 43. Ocular toxicity studies  2 species, including an albino rabbit with a large conjunctival sac  Initial single dose application: To decide exposure concentrations for repeated-dose studies Repeated dose study :  Duration subject to clinical use (Maximum of 90 days)  2 different concentrations exceeding human dose  In acute studies, one eye kept as control. A separate control group should be included in repeated-dose studies.
    44. 44. Ocular toxicity studies  Evaluation  Slit-lamp examination  To detect the changes in cornea, iris and aqueous humor.  Fluorescent dyes (sodium fluorescein, 0.25 to 1.0%)  To detect defects in surface epithelium  Intra-ocular tension monitored by a tonometer  Histological examination (fixation in Davidson’s or Zenker’s fluid)
    45. 45. Vaginal Toxicity Test  Rabbit or Dog  Topical application (vaginal mucosa) as pessary, cream or ointment  6-10 animals per dose group  Higher concentrations / several daily applications (in multiples of daily human dose)  7-30 days, as per clinical use  Observation parameters :  General : swelling, closure of introitus  Histopathology of vaginal wall
    46. 46. Rectal Tolerance Test  Preparations meant for rectal administration  In rabbits or dogs  6-10 animals per dose group  Volume comparable to human dose (or the maximum possible volume) to achieve administration of multiples of daily human dose  7-30 days, as per clinical use  Observation parameters  Clinical signs :- signs of pain, blood and/or mucus in faeces, condition of anal region/sphincter  Gross examination and (if required)  Histological examination of rectal mucosa
    47. 47. Parenteral Drugs  Intravenous/ intramuscular/ subcutaneous/ intradermal inj.  Injection sites in systemic toxicity studies examined grossly and microscopically  If needed, reversibility of adverse effects may be determined on a case to case basis
    48. 48. Inhalation toxicity studies  1 rodent and 1 non-rodent species  Acute, subacute and chronic toxicity studies according to the intended duration of human exposure  Gases and vapors given in whole body exposure chambers; aerosols are given by nose-only method  Dose (limit dose of 5mg/l) in multiples of human exposure  Particle size of 4 micron (especially for aerosols) with not less that 25% being 1 micron
    49. 49. Inhalation toxicity studies  3 dose groups and a control  Duration of exposure : maximum of 6 hr/day & 5 days/week Evaluation :  Respiratory rate, BALF examination, histological examination of respiratory passages and lung tissue  Regular parameters of systemic toxicity studies or assessment of margin of safety
    50. 50. Allergenicity / Hypersensitivity
    51. 51. Allergenicity / Hypersensitivity Any one of the standard tests:  Guinea pig :  Maximization test (GPMT)  Mouse :  Local lymph node assay (LLNA)
    52. 52. Guinea Pig Maximization Test Challenge (skin reaction appears) Induction : Minimum irritant dose (intradermal injection) Challenge : Maximum nonirritant dose (topical application) Doses are determined by a preliminary study Induction (immune response develops)
    53. 53. Main test  A minimum of 6 male and 6 female animals per group  One test group  One control group  One positive control group (preferable)  If no response : re-challenge 7-30 days after primary challenge
    54. 54. Induction (Day 0) 3 pairs of intradermal injections on either shoulders : • 0.1 ml Freund’s adjuvant alone • 0.1 ml test material (lowest irritant dose) • 0.1 ml test material in Freund’s adjuvant Day 7 : Topical patch at prepared shoulders (lowest irritant dose) Challenge (Day 21) Topical patch at prepared flanks (highest non-irritant dose) • Left side: Test agent • Right side: Vehicle Evaluation [Edema and Erythema] after 48 hr.
    55. 55. Local Lymph Node Assay  Mice of the same sex, either only males or only females  Drug treatment given on ear skin  3 graded doses (the highest being maximum nonirritant dose) plus vehicle control  A minimum of 6 mice per group Test material applied on ear skin on 3 consecutive days On day 5, i.v. 3H-thymidine / bromo-deoxy-uridine (BrdU) Draining auricular lymph nodes dissected after 5 hrs Evaluation : Increase in 3H-thymidine or BrdU incorporation
    56. 56. Genotoxicity
    57. 57.  Genotoxic compounds are presumed to be trans-species carcinogens, need not require long-term carcinogenicity studies  If intended for chronic administration, a chronic toxicity study (up to one year) to detect early tumorigenic effects ICH Standard Tests are generally conducted • In vitro test for gene mutation in bacteria • In vitro cytogenetic evaluation of chromosomal damage : • Mammalian cells or • Mouse lymphoma tk assay • In vivo test for chromosomal damage using rodent hematopoietic cells
    58. 58. Ames’ Test ( Bacterial Reverse Mutation Assay )  S. typhimurium tester strains TA98, TA100, TA102, TA1535, TA97 or  Escherichia coli WP2 uvrA or Escherichia coli WP2 uvrA  In-vitro exposure at a minimum of 5 log dose levels  “Solvent” and “positive control”  2.5 fold (or more) increase in number of revertants in comparison to spontaneous revertants are considered positive
    59. 59. In-vitro cytogenetic assay  Performed in CHO cells or on human lymphocyte in culture  In-vitro exposure using a minimum of 3 log doses  “Solvent” and “positive control”  [Positive control : Cyclophosphamide / Mitomycin C gives a reproducible and detectable increase in clastogenic effect]  > 50% inhibition of cells is considered significant
    60. 60. Mammalian cell test systems Division stimulated with phytohemagglutin Division arrested in metaphase using a spindle inhibitor Evaluation by light microscopy Increased number of aberrations in metaphase chromosomes
    61. 61. In Vitro Mouse Lymphoma TK Assay Mouse TK lymphoma cells Thymidine kinase (TK) enzyme involved in salvage pathway for incorporation of thymidine into cells via phosphorylation Trifluorothymidine (TFT) also phosphorylated by TK Cells containing TK are sensitive to toxic effects of TFT Forward mutations from TK+ to TK- result in loss of TK activity Quntifiication of mutant cells : Cells with TFT resistance
    62. 62. In Vivo Tests for Chromosomal Damage Mammalian Bone Marrow Chromosomal Aberration Assay Rodent Erythrocyte Micronucleus Assay
    63. 63. In-vivo cytogenetic assay Clastogenic & Aneugenic effects in metaphase chromosomes (min 100) Bone marrow : Giemsa staining Sacrificed 2 hours after colchicine administration Dosing on day 1 followed by i.p. colchicine administration at 22 hours • One rodent species (preferably rat) • Route of administration same as intended for humans • 5 animals/sex/dose groups • 3 dose levels, “solvent” and “positive” control (Cyclophosphamide)
    64. 64. In-vivo micronucleus assay ↑micronuclei in polychromatic erythrocytes [M-PCE] (min 1000) Bone marrow : Smeared with May Gruenwald / Giemsa stain Sacrifice of animals 6 hours after the last injection Dosing : day 1 and 2 of study • 1 rodent species (preferably mouse) needed • Route of administration of test substance same as humans • 5 animals / sex / dose groups • At least 3 dose levels, plus “solvent” and “positive” control • Positive control : mitomycin C or cyclophosphamide
    65. 65. Carcinogenicity
    66. 66. Carcinogenicity  For expected clinical use more than 6 months  For drugs used frequently in an intermittent manner  If concern about the carcinogenic potential due to :  Previous demonstration in the product class  Structure-activity relationship suggests carcinogenic risk  Preneoplastic lesions in repeated dose toxicity studies  Long-term tissue retention results in reactions
    67. 67. Carcinogenicity  Where life-expectancy in the indicated population is short (i.e., less than 2 - 3 years) - no long-term carcinogenicity studies  Where therapy is generally successful, there may be later concerns regarding secondary cancers. So carcinogenicity studies needed  A rodent species (preferably rat). Mouse only if justified  Strain should not have normal incidence of spontaneous tumors
    68. 68. Carcinogenicity  At least 3 dose levels :  Highest dose : sub-lethal, should not reduce life span of animals by more than 10% of expected normal  Lowest dose : should be comparable to the intended human therapeutic dose or a multiple of it, e.g. 2.5x; to make allowance for the sensitivity of the species  Intermediate dose : placed logarithmically between the other 2  Untreated control and (if indicated) a Vehicle control group
    69. 69. Carcinogenicity  Life span comparable to human’s over which drug use is intended  Generally, 24 months for rats and 18 months for mice  Atleast 50 animals of each sex  Observation parameters  Physiology, Behaviour, Biochemistry, Pathology  Comprehensive descriptions of benign and malignant tumour development, time of their detection, site, dimensions, histological typing etc
    70. 70. Carcinogenicity
    71. 71. Requirements of Clinical Trials and Marketing
    72. 72. Clinical trials & marketing- Requirements Systemic Toxicity Studies -oral/parenteral/ transdermal route Duration of proposed human administration Human phases for which study is proposed to be conducted Species Long term toxicity requirement Upto 1 week I, II, III 2 2 weeks 1-2 weeks ” ” 4 weeks 2-4 weeks ” ” 12 weeks > 1 month ” ” 24 weeks
    73. 73. Systemic toxicity studies – Inhalational route Duration of proposed human administration Human phases for which study is proposed to be conducted Species Long term toxicity requirments Upto 2 wk I, II, III 2 1 month (exposure time 3hr/d, 5d/wk) Upto 4 wk I, II, III 2 3 months (exposure time 6hr/d, 5d/wk) > 4 wks I, II, III 2 6 months (exposure time 6hr/d, 5d/wk)
    74. 74. Local Toxicity Studies Route Duration of Clinical trial Phase Species Duration of Toxicity study Dermal Ocular Otic Nasal Vaginal Rectal Upto 2 weeks I, II 1 4 wk III 2 4 wk > 2 weeks I,II,III 2 12 wk